Tempus and Medtronic have uncovered the potential of artificial intelligence (AI)-driven electronic clinician notifications (ECNs) in improving outcomes and supporting health equity in patients with valvular heart disease.
In the cluster-randomised, interventional ALERT study (NCT06099665), the companies evaluated whether automated alerts issued by the device-agnostic Tempus Next platform could improve the treatment of patients with mitral regurgitation (MR) and aortic stenosis (AS). The trial specifically looked at the impact of the electronic health record (EHR)-based technology on evaluation speed and treatment access.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
During this trial, the health technology was proven superior to usual care, with patients in the alert group being 27% more likely to be evaluated by a multidisciplinary cardiovascular team compared with the usual care arm in 90 days, meeting the trial’s primary endpoint.
This also translated into a 40% relative uptick in valve procedures within the Tempus Next group, with 13.4% of patients receiving treatment of this nature over the 9.6% in the usual care arm of the trial.
The Tempus Next system acts by processing and picking out important, real-time information from a patient’s echocardiogram report. This allows clinicians to receive an automatic notification on a patient’s cardiovascular state, which can facilitate early treatment interventions in a bid to improve outcomes.
Supporting equity in cardiovascular care
While the treatment options for cardiovascular disease continue to improve, there are still several treatment gaps that the medtech and pharma sectors must address – including the health disparities that impact patients with cardiovascular conditions like MR or AS.
According to Kendra Grubb, VP and CMO of Medtronic’s Structural Heart division, technologies like the Tempus Next system can close treatment gaps by ensuring that more patients have access to evaluations and life-saving interventions in a timely manner.
Tempus also designed its platform to promote treatment equity, as the company hopes that EHR-integrated clinical decision-making can offer as a “scalable safety net” to standardise the care delivery process and facilitate access to treatment across the entire patient population.
Currently, cloud-based systems are dominating the EHR market over remote systems in terms of revenue across the EU5 (France, Germany, Italy, Spain and the UK). However, analysts forecast a gradual closing of this gap, with remote systems set to constitute 39% of the market in 2033 at the end of the forecast period.
Elsewhere in the world of digital health, regulatory apps are bursting onto the scene, with a report from Clinical Trials Arena’s parent company, GlobalData forecasting that the category will experience strong double-digit growth between 2024 and 2034.
